摘要：目的 探讨雷替曲塞单药三线化疗在晚期结直肠癌治疗中的疗效及安全性。方法 选择2014年4月～2015年3月在我院收治的单药使用雷替曲塞的40例晚期结直肠患者，采用雷替曲塞单药3mg/m2，第1d，每21d为1个周期，2周期后行胸腹部CT评价疗效，并评价不良反应，评价疾病疗效直至出现疾病进展。结果 40列患者中CR 0 例(0%)，PR 2例(5%)，SD 22例(55%)，PD 16例(40%)，总有效率(CR+PR)为5%。PFS 为3.25个月。结论 主要不良反应为骨髓抑制、恶性呕吐、转氨酶升高，无治疗相关性死亡患者，也无因毒性反应而推迟，反应轻微，可耐受。

    关键词：雷替曲塞；晚期结直肠癌；三线化疗

    Abstract：Objective To study the clinical outcome and safety of raltitrexed single in third-line chemotherapy of advanced colorectal cancer. Method s 40 patients with advanced colorectal cancer who were administered with raltitrexed in third-line therapy between Apirl 2014 and March 2015 in our hospital were enrolled. The curative effects in each patient were evaluated every 2 cycles until the disease progression. Results There were 2 patients(5%) with PR ......